Zevra Therapeutics, Inc. last reported quarterly results on Nov 3, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $37.8 million (+44.9% year over year) and diluted EPS of $0.26. It usually reports 34–68 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 8, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Mar 9, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 34–68 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 3, 2026
34 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
38
+44.9%
|
19
+3630.9%
|
0.26
+2700.0%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
40
+53.3%
|
9
-88.3%
|
0.14
-88.4%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
36
+77.5%
|
38
+1322.7%
|
0.60
|
|
Mar 9, 2026
68 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
34
+183.4%
|
12
+134.0%
|
0.20
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
26
+605.4%
|
-1
+98.4%
|
-0.01
|
|
Aug 12, 2025
43 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
26
+481.7%
|
75
+474.9%
|
1.21
|
|
Apr 7, 2025
7 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
20
+495.6%
|
-3
+81.4%
|
—
|
|
Mar 11, 2025
70 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
12
-6.8%
|
-36
-79.7%
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZVRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1434647
- Former names
- KEMPHARM, INC (until Feb 24, 2023); KEMPHARM INC (until Jun 30, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.